Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Completed · Phase 1

Conditions studied: Neuroblastoma

In brief

This is a safety / feasibility trial evaluating the combination of a humanized anti-GD2 antibody (HU14.18K322A) manufactured at the Children's GMP, LLC at St. Jude with allogeneic natural killer (NK) cells and standard chemotherapy in children with relapsed or refractory neuroblastoma.

Key facts

Study ID

NCT01576692

Run by

St. Jude Children's Research Hospital

People needed

34

Starts

2012-04-01

Expected to finish

2018-10-17

Last updated by the study team

2018-11-15

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.